Gyre Therapeutics, Inc.
GYRE
$7.64
$0.060.79%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 30.56M | 26.77M | 22.06M | 27.87M | 25.49M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 30.56M | 26.77M | 22.06M | 27.87M | 25.49M |
| Cost of Revenue | 1.63M | 1.15M | 894.00K | 1.18M | 958.00K |
| Gross Profit | 28.94M | 25.62M | 21.16M | 26.70M | 24.53M |
| SG&A Expenses | 19.65M | 20.02M | 15.80M | 22.32M | 17.52M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.64M | 24.60M | 19.79M | 27.21M | 21.26M |
| Operating Income | 6.93M | 2.17M | 2.27M | 663.00K | 4.23M |
| Income Before Tax | 7.63M | 2.24M | 4.64M | 772.00K | 3.93M |
| Income Tax Expenses | 1.69M | 662.00K | 901.00K | 203.00K | 1.07M |
| Earnings from Continuing Operations | 5.94M | 1.58M | 3.73M | 569.00K | 2.86M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -2.33M | -1.13M | -1.04M | -668.00K | -1.73M |
| Net Income | 3.61M | 442.00K | 2.70M | -99.00K | 1.12M |
| EBIT | 6.93M | 2.17M | 2.27M | 663.00K | 4.23M |
| EBITDA | 7.58M | 2.81M | 2.81M | 1.13M | 4.68M |
| EPS Basic | 0.04 | 0.01 | 0.03 | 0.00 | 0.01 |
| Normalized Basic EPS | 0.03 | 0.00 | 0.02 | 0.00 | 0.01 |
| EPS Diluted | 0.03 | 0.00 | 0.00 | 0.00 | 0.01 |
| Normalized Diluted EPS | 0.02 | 0.00 | 0.02 | 0.00 | 0.01 |
| Average Basic Shares Outstanding | 90.85M | 89.12M | 86.42M | 85.95M | 85.64M |
| Average Diluted Shares Outstanding | 103.97M | 102.70M | 101.97M | 85.95M | 102.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |